Peer-Reviewed by Dr. Marcus Vance, MD, PhD
Lead Clinical Pharmacologist, Institute for Clinical Pharmacology & Safety — Board-certified in Clinical Pharmacology & Toxicology. Reviewed for scientific accuracy against current FDA label documentation, WHO technical monographs, and peer-reviewed literature.
Origins and Pharmacological Classification
Stromectol—the brand-name formulation of ivermectin for oral human use—belongs to the macrocyclic lactone class of antiparasitic agents. Its discovery traces back to soil samples collected in Japan during the early 1970s, from which the actinomycete Streptomyces avermitilis was isolated. What emerged from that culture broth was avermectin, a compound of remarkable biological potency and surprising structural complexity. The semi-synthetic derivative, ivermectin, was developed from the 22,23-dihydro variant of avermectin B1 and received FDA approval for human use in 1987. William C. Campbell and Satoshi Ōmura shared a Nobel Prize in Physiology or Medicine in 2015 in recognition of this discovery—a fact that underscores just how significant this molecule proved to be.
Mechanism of Action
The primary mechanism is well-characterized. Ivermectin binds with high affinity and selectivity to glutamate-gated chloride ion channels (GluCl channels) present in the peripheral nerve and muscle cells of invertebrates. This binding—irreversible under physiological conditions—causes sustained channel opening, leading to increased permeability to chloride ions across the cell membrane. Hyperpolarization follows. The organism is paralyzed. Death ensues.
Why doesn't this happen in mammals? Mammals possess glutamate-gated chloride channels, but these are confined to the central nervous system and are normally inaccessible to ivermectin because the drug does not readily cross an intact blood-brain barrier (BBB) at approved therapeutic doses. P-glycoprotein (P-gp), a membrane efflux pump encoded by the ABCB1 gene, actively transports ivermectin out of CNS tissue. This efflux mechanism constitutes a key component of the drug's mammalian safety margin. Patients with mutations in the ABCB1 gene—and animals such as Collies carrying the MDR1 deletion—demonstrate elevated CNS sensitivity, an important clinical and pharmacogenomic consideration.
Pharmacokinetics at a Glance
After oral administration, ivermectin is absorbed from the gastrointestinal tract with peak plasma concentrations (Cmax) typically achieved within 4 hours. Bioavailability is enhanced considerably when the drug is taken with a high-fat meal—studies have documented a two- to four-fold increase in systemic exposure compared to fasted administration. The drug is extensively protein-bound (approximately 93%), predominantly to albumin, which influences its volume of distribution (estimated at 46.9 L/kg in some studies).
Hepatic metabolism via cytochrome P450 enzymes—particularly CYP3A4—produces at least seven metabolites, none of which are known to carry significant pharmacological activity. Elimination occurs primarily through the feces; urinary excretion accounts for less than 1% of administered dose. The terminal plasma half-life in adults falls in the range of 12–36 hours, though tissue-bound drug persists somewhat longer. These parameters form the quantitative backbone of rational dosing strategies.
FDA-Approved Clinical Indications
In the United States, oral Stromectol carries FDA approval for two specific parasitic indications:
- Intestinal strongyloidiasis — infection caused by the nematode Strongyloides stercoralis, capable of causing hyperinfection syndrome in immunocompromised individuals.
- Onchocerciasis — caused by the filarial nematode Onchocerca volvulus, the etiological agent of river blindness. A single annual or semi-annual dose has proven sufficient to suppress microfilaridermia within mass drug administration programs.
Separate topical ivermectin formulations—Soolantra 1% cream and Sklice 0.5% lotion—carry approval for papulopustular rosacea and head lice, respectively. These are distinct formulations from oral Stromectol and should not be conflated with systemic pharmacotherapy.
Safety Profile: What the Evidence Actually Shows
Decades of mass drug administration have generated a safety dataset of extraordinary breadth. The Mectizan Donation Program, spanning more than 30 years and billions of treatments, documents an adverse event profile that is predominantly mild. Commonly reported reactions include fever, pruritus, skin rash, headache, dizziness, and peripheral or facial edema. Critically, most of these reactions represent the Mazzotti reaction—a systemic immune response to dying microfilariae—rather than direct drug toxicity.
Severe neurological adverse events have been reported, albeit rarely. The majority of documented CNS cases involve either extraordinarily high doses, concurrent use of CNS depressants such as benzodiazepines or barbiturates, underlying ABCB1 polymorphisms, or co-infection with high Loa loa microfilarial loads. This last concern—encephalopathy triggered by rapid destruction of Loa loa microfilariae—is relevant primarily in Central African populations and has prompted WHO-developed pre-treatment screening protocols.
At standard therapeutic doses in healthy adult populations without the above risk factors, the safety profile of Stromectol is well-established and favorable.
A Note on Off-Label Use and Regulatory Guidance
It would be difficult to discuss Stromectol's pharmacological profile in 2024 without acknowledging the extraordinary volume of off-label research published after 2020. ICPS takes no institutional position on investigational applications. What the evidence compels us to state plainly: the FDA, EMA, WHO, and NIH have not approved ivermectin for any indication beyond those listed on the current label. Prescribers operating within the bounds of accepted clinical pharmacology should consult current regulatory guidance and peer-reviewed systematic reviews before considering off-label use.
This institute exists to clarify—not to amplify noise. The pharmacological data for Stromectol are, on their own terms, genuinely compelling.